Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy

References

• Bloomberg News. The U.S. pays a lot more for top drugs than other countries; 2015. http://www.bloomberg.com/graphics/2015-drug-prices/ [Last accessed July 2016]
   Google Scholar
• Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004;17:209-16
   PubMed Web of Science ®Google Scholar
• Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 2006;70:1358-66
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-55
   PubMed Web of Science ®Google Scholar
• Natoli JL, Boer R, Nathanson BH, et al. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol 2013;14:88
   PubMed Web of Science ®Google Scholar
• Conzo G, Della Pietra C, Tartaglia E, et al. Long-term function of parathyroid subcutaneous autoimplantation after presumed total parathyroidectomy in the treatment of secondary hyperparathyroidism. A clinical retrospective study. Int J Surg 2014;12(Suppl1):S165-S9
   Web of Science ®Google Scholar
• Evolve Trial Investigators, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94
   PubMed Web of Science ®Google Scholar
• Bensink ME, Lozano-Ortega G, Block GA, et al. A Bayesian meta-analysis of clinical and observational studies of cinacalcet and clinical outcomes in secondary hyperparathyroidism. American Society of Nephrology Kidney Week, San Diego (CA); November 3–8, 2015
   Google Scholar
• Reams BD, et al. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective new-user cohort design. BMC Nephrol 2015;16:175
   PubMed Web of Science ®Google Scholar
• Block GA, Bushinsky DA, Cunningham J, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA 2017;317:146-55
   PubMed Web of Science ®Google Scholar
• Block GA, Bushinsky DA, Cheng S, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA 2017;317:156-64
   PubMed Web of Science ®Google Scholar
• Gutiérrez OM1, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-92
   PubMed Web of Science ®Google Scholar
• Stollenwerk B, Iannazzo S, Akehurst R, et al. Assessing the cost-utility of etelcalcetide: a Markov model. ISPOR 19th Annual European Congress; 2016
   Google Scholar
• Belozeroff V, Chertow GM, Graham CN, et al. Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health 2015;18:1079-87
   PubMed Web of Science ®Google Scholar
• Stollenwerk B, Dehmel B, Akehurst R, et al. Modelling etelcalcetide effectiveness on health outcomes: relating biochemical outcomes to mortality, cardiovascular events, fractures and parathyroidectomy. Submitted to: Society for Medical Decision Making (SMDM), 16th Biennial European Conference. London, 14 June 2016
   Google Scholar
• Briggs AH, Parfrey PS, Khan N, et al. Analyzing health-related quality of life in the EVOLVE trial: the joint impact of treatment and clinical events. Med Decis Making 2016;36:965-72
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Red Book; 2013. www.micromedexsolutions.com. [Last accessed July 2013]
   Google Scholar
• Garrison Jr LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report. Value Health 2007;10:326-35
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Data on File, IMS Health; 2015. US data
   Google Scholar
• ARO – “Analyzing Data, Recognizing Excellence and Optimizing Outcome” database, data on file
   Google Scholar
• St Peter WL, Li Q, Liu J, et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 2009;4:354-60
   PubMed Web of Science ®Google Scholar
• Martin KJ, Block G, Cheng S, et al. Interim analysis of a multicenter single-arm extension study to describe the long-term safety of etelcalcetide (AMG 416) in the treatment of secondary hyperparathyroidism in subjects with chronic kidney disease on hemodialysis. Chicago (IL): American Society of Nephrology (ASN); 2016
   Google Scholar
• New DDDs. World Health Organization. https://www.whocc.no/atc/lists_of_new_atc_ddds_and_altera/new_ddds/. [Last accessed June 1, 2017]
   Google Scholar
• Federal Register/Vol. 75, No. 155/Thursday, August 12, 2010/Rules and Regulations. Department of Health and Human Services. Centers for Medicare & Medicaid Services. 42 CFR Parts 410, 413 and 414 [CMS–1418–F] RIN 0938–AP57. Medicare Program; End-Stage Renal Disease Prospective Payment System
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks. Draft report. September 8, 2015. [Last accessed November 2015]
   Google Scholar
• Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ 2012;15:509-20
   PubMedGoogle Scholar
• Ubel PA, Berry SR, Nadler E, et al. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Aff (Millwood) 2012;31:709-17
   PubMed Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
   PubMed Web of Science ®Google Scholar
• Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii, xi-xiii, 1-167
   Web of Science ®Google Scholar
• Eandi M, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010;28:1041-54
   PubMed Web of Science ®Google Scholar
• Conzo G, Perna AF, Napolitano S, et al. Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report. J Med Case Rep 2012;6:417
   PubMedGoogle Scholar
• Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 2015;132:27-39
   PubMed Web of Science ®Google Scholar
• Grima DT, Bernard LM, Dunn ES, et al. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. Pharmacoeconomics 2012;30:981-9
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the methods of technology appraisal: National Institute for Health and Care Excellence (NICE); 2013
   Google Scholar